M8095647
Beraprostsodiumsalt , 98% , 88475-69-8
Synonym(s):
2,3,3a,8b-Tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran-5-butanoic acid sodium salt;Procyclin;TRK 100
| Pack Size | Price | Stock | Quantity |
| 1mg | RMB2573.60 | In Stock |
|
| others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
| Melting point: | 204-206°C |
| storage temp. | -20°C |
| solubility | DMF:77.0(Max Conc. mg/mL);183.12(Max Conc. mM) Ethanol:20.0(Max Conc. mg/mL);47.56(Max Conc. mM) PBS (pH 7.2):19.0(Max Conc. mg/mL);45.19(Max Conc. mM) |
| form | powder |
| color | white to beige |
| InChIKey | YTCZZXIRLARSET-LIIFYGAANA-M |
| SMILES | [C@H]12[C@H](C[C@@H](O)[C@@H]1/C=C/[C@@H](O)C(C)CC#CC)OC1C(=CC=CC2=1)CCCC([O-])=O.[Na+] |&1:0,1,3,5,8,r| |
| CAS DataBase Reference | 88475-69-8(CAS DataBase Reference) |
Description and Uses
Beraprost sodium is a new, orally active antithrombotic epoprostenol analog introduced as a treatment for peripheral vascular disease, including Raynaud's syndrome and Buerger's disease. The antiplatelet activity may be due to its elevation of cyclic AMP in platelets which is achieved by activating adenylate cyclase in the platelet membrane, followed by the inhibition ofCa++- influx and thromboxane A2 formation.
Platelet aggregation inhibitor; stable analog of Prostacyclin. Antithrombotic; vasodilator (peripheral).
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315-H319-H335 |
| Precautionary statements | P261-P264-P271-P280-P302+P352-P305+P351+P338 |
